These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 14659328)

  • 21. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
    Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
    Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/cyclophosphamide (FEC).
    Yan PW; Huang XE; Jiang Y; Tang JH; Xu HX; Xu X; Jin X
    Asian Pac J Cancer Prev; 2010; 11(4):1115-8. PubMed ID: 21133634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
    Conte PF; Baldini E; Michelotti A; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Giannessi PG; Gentile A
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):39-42. PubMed ID: 8996597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
    Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
    Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer.
    Margolin S; Bengtsson NO; Carlsson L; Edlund P; Hellstrøm M; Karlsson P; Lidbrink E; Linderholm B; Lindman H; Malmström P; Pettersson Skøld D; Søderberg M; Villman K; Bergh J;
    Acta Oncol; 2011 Jan; 50(1):35-41. PubMed ID: 21174610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
    Chua S; Smith IE; A'Hern RP; Coombes GA; Hickish TF; Robinson AC; Laing RW; O'Brien ME; Ebbs SR; Hong A; Wardley A; Mughal T; Verrill M; Dubois D; Bliss JM;
    Ann Oncol; 2005 Sep; 16(9):1435-41. PubMed ID: 15946977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase II clinical trial and biomarker analysis of paclitaxel plus epirubicin versus vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations.
    Jiang YZ; Ge LP; Jin X; Fan L; He M; Liu Y; Chen L; Zuo WJ; Wu J; Liu GY; Di GH; Wang ZH; Yu KD; Shao ZM
    Breast Cancer Res Treat; 2021 Jan; 185(2):371-380. PubMed ID: 32975708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of paclitaxel treatment in pre-operative or post-operative does not affect survival in breast cancer patients.
    Wang J; Chen S; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
    Thorac Cancer; 2017 May; 8(3):246-250. PubMed ID: 28402606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
    Abrial C; Van Praagh I; Delva R; Leduc B; Fleury J; Gamelin E; Sillet-Bach I; Penault-Llorca F; Amat S; Chollet P
    Oncologist; 2005 Apr; 10(4):242-9. PubMed ID: 15821244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.
    Perez EA
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S52-6. PubMed ID: 11970750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vinorelbine, epirubicin and fluorouracil as first-line therapy in metastatic breast cancer--a phase II trial.
    Elomaa I; Joensuu H; Blomqvist C
    Acta Oncol; 2003; 42(4):309-14. PubMed ID: 12899502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma.
    Fornier MN; Seidman AD; Theodoulou M; Moynahan ME; Currie V; Moasser M; Sklarin N; Gilewski T; D'Andrea G; Salvaggio R; Panageas KS; Norton L; Hudis C
    Clin Cancer Res; 2001 Dec; 7(12):3934-41. PubMed ID: 11751485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety.
    Shimada H; Ueda S; Saeki T; Shigekawa T; Takeuchi H; Hirokawa E; Sugitani I; Sugiyama M; Takahashi T; Matsuura K; Yamane T; Kuji I; Hasebe T; Osaki A
    Jpn J Clin Oncol; 2015 Jul; 45(7):642-9. PubMed ID: 25989989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
    Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
    J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.
    Esteban E; de Sande G; Puertas J; Fra J; Palacio I; Vieitez JM; Fernández JL; Muñiz I; Modollel A; Carrasco J; Sala M; Lacave AJ
    Breast Cancer Res Treat; 2000 Jul; 62(2):127-33. PubMed ID: 11016750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
    Vici P; Foggi P; Colucci G; Capomolla E; Brandi M; Giotta F; Gebbia N; Di Lauro L; Valerio MR; Paoletti G; Belli F; Pizza C; Giannarelli D; Lopez M
    Anticancer Res; 2005; 25(2B):1309-14. PubMed ID: 15865083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
    Fountzilas G; Papadimitriou C; Aravantinos G; Nicolaides C; Stathopoulos G; Bafaloukos D; Kalofonos H; Ekonomopoulos T; Skarlos D; Pavlidis N; Dimopoulos AM
    Oncology; 2001; 60(3):214-20. PubMed ID: 11340372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.